INTAS

INTAS is one of the world's leading pharmaceutical development, manufacturing, and marketing companies, with an average annual growth rate of approximately 25.5% over the past five years. It surpassed the US$1.9 billion mark in the last fiscal year. The company has established subsidiaries in the European Union, the United States, Canada, South Africa, Australia, the Asia-Pacific region, as well as in the CIS and Middle Eastern regions. INTAS operates in 85 countries, with more than 69% of its revenue coming from global operations. Currently ranked ninth in India’s pharmaceutical market, it is the largest privately-owned generic drug company in the country. INTAS leads in key therapeutic areas in India, including the central nervous system, cardiothoracic, diabetes, gastroenterology, urology, and oncology. The company is also renowned for its product portfolio in hospital treatment departments across the EU and the United States. INTAS allocates 6-7% of its revenue to research and development, with over 10,000 registered products globally and more than 300 high-value FTF/FTM, biosimilar, and NDD products. Its plasma separation technology is a pioneer in the production of plasma-derived therapies. The company features well-established R&D laboratories, advanced GMP-certified manufacturing facilities, and GLP-compliant QC laboratories. Our core values are innovation, customer delight, ownership and collaboration, focus on performance, and social responsibility, which drive our pursuit of excellence.